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Abstract: In order to address preserved protein bioactivities and protein sustained-release 
problems, a method for preparing double-walled microspheres with a core (protein-loaded nano-
particles with a polymer-suspended granule system-formed core) and a second shell (a polymer-
formed shell) for controlled drug release and preserved protein bioactivities has been developed 
using (solid-in-oil phase-in-hydrophilic oil-in-water (S/O/Oh/W)) phases. The method, based 
on our previous microsphere preparation method (solid-in-oil phase-in-hydrophilic oil-in-water 
(S/O/Oh/W), employs different concentric poly(D,L-lactide-co-glycolide), poly(D,L-lactide), and 
protein-loaded nanoparticles to produce a suspended liquid which then self-assembles to form 
shell-core microspheres in the hydrophilic oil phase, which are then solidified in the water phase. 
Variations in the preparation parameters allowed complete encapsulation by the shell phase, 
including the efficient formation of a poly(D,L-lactide) shell encapsulating a protein-loaded 
nanoparticle-based poly(D,L-lactide-co-glycolide) core. This method produces core-shell double-
walled microspheres that show controlled protein release and preserved protein bioactivities for 
60 days. Based upon these results, we concluded that the core-shell double-walled microspheres 
might be applied for tissue engineering and therapy for chronic diseases, etc.
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Introduction
Encapsulation of proteins or peptides within biodegradable and biocompatible polymers 
is a successful and well-documented method for their sustained or controlled-release. 
The benefits of sustained or controlled-release microsphere systems include avoid-
ance of resistance in bacteria1–4 and pulsatile administration of vaccines to enhance 
immune response, etc.5,6 Biodegradable and biocompatible polymer microspheres 
are most often prepared using water-in-oil-in-water (W/O/W), water-in-oil (W/O), 
or solid-in-oil-in-water (S/O/W) methods with poly(D,L-lactide-co-glycolide), and 
poly(D,L-lactide) due to their proven safety.7 In this process, an aqueous solution of 
the protein, or of protein and an additive, is added to an organic solution of the poly-
mer of choice to form an emulsion. This emulsion is then added to a large quantity 
of surfactant (polyvinyl alcohol, PVA) and an aqueous salt (sodium chloride) solu-
tion and the resulting solution is stirred until the solvent evaporates and the polymer 
microspheres solidify.
However, because proteins are large hydrophilic molecules and difficult to encap-
sulate within hydrophobic polymers, a high rate of mixing is employed to entrap the 
protein into pockets of water solution inside the hardened polymer microspheres, 
followed by freeze-drying.8 This results in some proteins locating near the surfaces 
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of the microspheres. This can result in an initial burst of 
protein within the first 24 hours of placement in a PBS 
release solution both in vitro or in vivo.9,10 While some 
formulation optimization can be employed to enhance the 
efficacy of controlled- or sustained-release of protein from 
single-walled polymer microspheres,11 a better alternative for 
controlled- or sustained-release protein above that achievable 
for single-walled microspheres is through the use of core-
shell (double-walled) microspheres.12,13
Core-shell polymer microspheres are often composed of two 
distinct polymers in a core and shell orientation. The mechanism 
for creation of core-shell polymer microspheres is through 
polymer–polymer phase separation of two immiscible polymers 
in solution.14 Localizing the drug to the core of microspheres 
increases the amount of material through which the drug must 
diffuse, thereby slowing the drug-release rate.15 Core-shell 
microspheres have been developed to encapsulate bovine serum 
albumin (BSA),12 etanidazole,16 doxorubicin,17 5-fluorouracil,18 
and piroxicam,19 etc. These core-shell microspheres, to some 
extent, improve and extend the in vitro release profiles and 
release period of these   compounds. These previous studies all 
used core-shell microspheres prepared using methods based on 
surface of water–oil or water–air (for example, water-in-oil-in-oil 
(W/O/O), or oil-in-oil-in-water (O/O/W) preparation.16,20 How-
ever, these methods result in direct exposure of the protein mol-
ecule to water–air or water–oil interfaces, which can often result 
in protein denaturation.21 For the same reason, core-shell 
microsphere systems often show low encapsulation efficiency 
for hydrophilic proteins.12 Therefore, this paper concentrates 
on core-shell double-walled microspheres based upon a solid-
in-oil-in-hydrophilic oil-in-water emulsion method, to address 
these problems.
To overcome the problems associated with core-shell 
microspheres (oil–water or water–air surface, low encapsula-
tion efficiency, burst release, protein aggregation, etc) and 
to preserve protein bioactivity, we investigated the use of an 
aqueous phase-aqueous phase emulsion method for production 
of protein-loaded dextran nano/microparticles.21–24 The dextran 
nano/microparticle preparation method was aimed at overcom-
ing the issue of protein being directly exposed to all kinds of 
surfaces and used a solid-in-oil-in-hydrophilic oil-in-water 
(S/O/Oh/W)25 or solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/
Oh/E)26 method. This improved the encapsulation efficiency and 
the bioactivity of the released protein. Up till now, the encap-
sulation of protein-loaded dextran nanoparticles within core-
shell microspheres has not been developed using S/O/Oh/W 
or S/O/Oh/E emulsion methods. The purpose of this study was 
to develop a method for   preparing core-shell microspheres in 
which the proteins BSA, myoglobin, and β-galactosidase) were 
encapsulated within a core of poly(D,L-lactide-co-glycolide) 
(PLGA), which was then further surrounded by a shell of 
poly(D,L-lactide) (PLA). The effects of different factors and 
the composition of the hydrophilic oil were also investigated. 
Myoglobin, BSA, and β-galactosidase were chosen as model 
proteins for characterizing the efficacy of protein-delivery 
systems from core-shell microspheres because of their small 
sizes (17.2 kDa, 66.2 kDa, and 130.0 kDa, respectively), 
which are similar to those of therapy proteins used in clin-
ics. In addition, the bioactivity of β-galactosidase could be 
easily measured with a β-galactosidase kit, and the aggrega-
tions of myoglobin and BSA could also be easily quantified 
by size exclusion high-performance liquid chromatography 
(SEC-HPLC) detection.
To confirm the distribution of proteins within the polymer 
core, BSA and myoglobin were encapsulated and their local-
ization to a particular polymer component was confirmed 
through microscopy. Burst release, encapsulation efficiency, 
protein aggregation, and preservation of protein bioactivity 
from the core-shell microspheres using the S/O/Oh/W or 
S/O/Oh/E emulsion method were investigated. The results 
confirmed that the core-shell microsphere systems had no 
bursting or aggregation, high encapsulation efficiency, and 
high preservation of protein bioactivities. The protein-release 
kinetics profiles from the core-shell microspheres studies 
were determined and the bioactivities of β-galactosidase 
were confirmed for the extended-release periods. The poten-
tial application of these core-shell microspheres might be 
in   tissue engineering and therapy for chronic diseases, etc. 
Therefore, a controlled- or sustained-release period of 
  proteins for 60 days was considered acceptable.
Materials and methods
Materials
PVA (biochemical reagent, average molecular weight [MW] 
9000–10,000, 80% hydrolyzed), polyethylene glycol (bio-
chemical reagent, PEG, MW 6000), dextran (biochemical 
reagent, MW 64,000–76,000), β-galactosidase (biochemical 
reagent, β-gal), and horse myoglobin (MGB) were purchased 
from Sigma-Aldrich (St Louis, MO). PLGA (lactide:glycolide 
1A, 2A, and 3A, (50:50), MW 6500, 20,000, and 40,000–
75,000 units) and PLA, Low IV and High IV (MW 40,000–
75,000 units) were obtained from SurModics Pharmaceuticals 
(Birmingham, AL). Sodium   dihydrogen phosphate (analytical 
reagent), ethylene glycol (EG, analytical reagent), 1,2-pro-
pylene glycol (PG, analytical reagent), glycerol (G, analytical 
reagent), PVA (biochemical reagent), polyvinyl-pyrrolidone 
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(PVP, biochemical reagent), poloxamer 188 (biochemi-
cal reagent), and trehalose were purchased from Chinese 
Medicine Group Chemical Reagent Corporation (Shanghai, 
People’s Republic of China) (analytical reagent). Dichlo-
romethane (DCM), ethyl acetate (analytical reagent), and 
PBS (analytical reagent) were all purchased from Sigma-
Aldrich. The Micro Bicinchoninic Acid (BCA) Protein Assay 
Kit (23235) was purchased from Pierce Protein Research 
Products (Rockford, IL).
Protein-loaded nano/microparticle  
preparation
A co-aqueous solution (3 mL) of dextran (0.5%, w/w), protein 
(0.25%, w/w), and PEG (5%, w/w) was mixed by vortex for 
0.5 minutes and then frozen in a freezer at −80°C overnight. 
The frozen samples were lyophilized using a Christ Alpha 1–2 
laboratory freeze dryer (Osterode, Germany) operated at a pres-
sure of 5.25 × 10−3 Pa for 24 hours. The lyophilized powders 
were suspended in 5 mL of DCM, followed by centrifugation 
at 12,000 rpm for 5 minutes on an Anker TGL-16C centrifuge 
(Shanghai, People’s Republic of China) to remove the PEG 
continuous phase. The washing–centrifugation procedure was 
repeated three times, and the microparticles were evaporated at 
1.33 Pa for 24 hours using a vacuum dryer (Fuma DZF-3, Shang-
hai Fuma Co, Ltd, Shanghai, People’s Republic of China) to 
remove solvent residues. The obtained microparticles contained 
less than 0.5% (w/w) PEG after the washing process.22–24
Core-shell microsphere preparation
The protein-loaded nanoparticles and different concentrations 
of PLGA solution in DCM were vortexed for 30–60 seconds 
to achieve a homogenous mixture. The mixture was then 
transferred to different glass vials containing different 
concentrations of PLA DCM solutions and vortexed for an 
additional 30–60 seconds. This solid-in-oil emulsion was 
added with a Pasteur pipette to 5 mL of different   compositions 
of hydrophilic oil containing aqueous 0.5% PVA and stirred at 
1200 rpm using a cruciform magnetic bar as a stirring rotor for 
30–60 seconds. The resulting solid-in-oil-in-hydrophilic oil 
emulsion was then transferred to a beaker containing 5% w/w 
sodium chloride (1 L aqueous solution) or 200 mL ethyl 
alcohol and stirred at 120 rpm for 4 hours or 30 minutes, 
respectively. The microspheres were collected by centrifuga-
tion (1200 rpm for 5 minutes) and washed four times using 
purified water (Figure 1). The microspheres were then lyo-
philized and stored with a desiccant at −20°C.
Microscopy observations
Optical microscopy (Olympus CX41 microscope equipped 
with a digital camera [model µ710; Tokyo, Japan]) was used 
to observe the progressive surface morphologies and core-
shell thickness of the microspheres during preparation. A few 
droplets of microsphere suspension in hydrophilic oil phase 
or of solidifying microspheres in aqueous solution for 3 hours 
were placed directly onto a microscopy sample holder, and 
then imaged or observed at various magnifications.
Scanning electron microscopy (SEM; FEI Sirion 2000 SEM 
system [Eindhoven, The Netherlands]) was also employed to 
image the surface and internal morphologies. Microsphere 
samples were cross-sectioned using a razor blade to allow 
observation of the internal structures of the microspheres. 
The samples were mounted on metal stubs with double-sided 
adhesive tape and vacuum-sputter-coated with two gold layers 
prior to the imaging at 5–10 keV .
Particle or microsphere size distribution
The size distribution and average particle size of the various 
particle or microsphere preparations were determined using 
a Particle Size and Shape Analyzer (CIS-100; Ankersmid, 
Nijverdal, the Netherlands). A 10 mg sample of dry particles 
Solid particles (Oil phase-1)
PLGA or PLA - PLGA DCM solution 
Oil phase-2
Second homogenize
First homogenize
Solidified MS Lyophilize
or drying
MS
Aqueous phase
(W)
Figure 1 Schematic diagram showing microsphere preparation. 
Abbreviations: PLgA, poly(D,L-lactide-co-glycolide); PLA, poly(D,L-lactide); DCM, dichloromethane; MS, microspheres.
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or microspheres was re-suspended in the quartz cuvette filled 
with isopropyl alcohol and stirred with a magnetic bar during 
the examination.
Protein content and β-galactosidase 
activity assays
For determining protein content from core-shell micro-
spheres, an accurately weighed 20 mg sample of dry core-
shell microspheres was re-dissolved in 6 mL of DCM, and 
then centrifuged at 12,000 rpm for 5 minutes to remove 
soluble PLGA and PLA from the mixture and to collect the 
solid nanoparticles. This washing process was repeated three 
times, and the nanoparticles were collected after evaporation 
of dichloromethane residues under a vacuum of 1.33 Pa for 
24 hours. Protein-loaded dextran nanoparticles obtained 
from the microspheres were then dissolved in an appropri-
ate volume of PBS (0.45 mol/L, pH 7.4) and the protein 
content was determined with a Micro-BCA kit. The amount 
of protein from each formulation was divided by the amount 
added in the formulation to give encapsulation efficiency. 
Loading was calculated using the following   equation:   loading 
(%) = P/M × 100, where P was the actual total weight of 
protein encapsulated into core-shell microspheres and M 
was the actual total weight of the harvested formulation 
microspheres.26
The activity of β-galactosidase from core-shell micro-
spheres was measured as hydrolysis of o-nitrophenyl-β-D-
galactopyranoside (ONPG) as previously described.27 Briefly, 
0.1 mL of a solution of β-galactosidase (authentic or obtained 
from core-shell microspheres), was added to a reaction mix-
ture consisting of 2.6 mL of PBS   buffer (pH 7.3), 0.1 mL 
of 30 mM MgCl2, 0.1 mL of 3.36M 2-mercaptoethanol, and 
0.1 mL of 68 mM ONPG. The mixed solution was incubated 
at 37°C for 5 minutes, then immediately cooled to 0°C. 
β-galactosidase activity was determined from absorbance 
readings for the reaction product of ONPG at 420 nm.27
Size-exclusion chromatography (SEC)
SEC assay was carried out using an HPLC system   (Shimadzu, 
Kyoto, Japan) equipped with a TSK G2000SWXL size-
exclusion column. The mobile phase was composed of 0.15 M 
sodium chloride and 50 mM sodium phosphate (PBS, pH 7.4). 
The chromatographic peaks were recorded at 214 nm. The 
aqueous protein solution sample was filtered through a 0.22 µm 
film and then loaded onto the HPLC   column. The flow rate of 
the mobile phase was 1.0 mL/minute. The amount of monomer 
or aggregate protein was calculated using   Shimadzu Chromato-
Solution-Light software (Kyoto, Japan).
In vitro protein release studies
For determining the protein-release kinetics from core-shell 
microspheres, 20 mg of core-shell microspheres were incu-
bated in 1 mL release medium (PBS) at 37°C and shaken at 
150 rpm (Shanghai Fun Wa KYC 100C; Shanghai, People’s 
Republic of China). The release medium was replaced by 
the same volume of fresh buffer each day and the protein 
concentration was assayed using the Micro-BCA or SEC-
HPLC method.
Statistical analysis
The data were expressed as means ± standard deviation. 
Statistical difference was sought using Student’s t-test. 
  Differences were considered statistically significant for 
P values lower than 0.05.
Results
Light microscopy analysis  
of core-shell microspheres
Core-shell microspheres were prepared using a solid-in-oil-in-
in-hydrophilic oil-in-water or solid-in-oil-in-hydrophilic oil-in-
ethanol emulsion method.22,23 The structures of the microspheres 
appeared as core and shell double-walled spheres (Figure 2 and 
Figure S1) in the hydrophilic oil phase   (unsolidified micro-
spheres) or the water (ethanol) phase (solidified microspheres). 
The microspheres were prepared using a 1:4:6 weight ratio of 
BSA-loaded dextran nanoparticles, PLG, and PLA in a con-
centration range from 12.5% to 25% (w/w) polymer solution 
in DCM. After the PLG, BSA-loaded dextran nanoparticles, 
and PLA were thoroughly mixed and added to a hydrophilic 
oil phase, the PLGA, BSA-loaded dextran nanoparticles, and 
PLA phase precipitated around the PLGA25 resulting in the 
core and shell morphology (Figure 2 and Figure S1). The 
average yield of prepared microspheres was ∼70% ± 10% 
(n = 5) from microspheres solidified in a water phase and 
80% ± 9% from microspheres solidified in an ethanol phase 
(n = 5). The mean microsphere diameter was 67 ± 20 µm, 
with the majority of microspheres ranging from 60 to 80 µm 
(Figure 3). SEM of these microspheres showed smooth and 
non-porous surfaces.
Protein-loaded dextran nanoparticle 
localization and polymer orientation  
of core-shelled microspheres
Light micrographs of core-shell microspheres encapsulating 
protein-loaded dextran nanoparticles revealed that the protein-
loaded dextran nanoparticles were localized within the polymer 
core (Figures 2 and 4, and Figure S1). BSA-loaded and 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
260
Yuan and LiuInternational Journal of Nanomedicine 2012:7
myoglobin-loaded nanoparticles were encapsulated into the 
microspheres, and the protein-loaded nanoparticles were found 
within the microsphere core   (Figures 2, 4, and Figure S1).
Kokai et al reported that protein (hydrophilic molecules) 
was easily encapsulated within the PLGA core of core-
shell microspheres.28 We think that protein-loaded dextran 
nanoparticles were also encapsulated into PLGA cores, 
because the dextran and protein were also hydrophilic 
molecules.
Protein encapsulation efficiency
The protein payload and encapsulation efficiency of core-
shell microspheres are shown in Tables 1–5. Factors such 
as surfactant, the molecular weights of PLGA and PLA, 
and hydrophilic oil, etc affected the protein encapsulation 
efficiency of core-shell microspheres.
A B B 100 µm
D
D
C
C
A
E F
E F
100 µm 100 µm 100 µm
100 µm 100 µm
100 µm 100 µm
100 µm 100 µm
100 µm 100 µm
I: Microspheres in the hydrophilic oil phase II: Hardening microspheres in the water phase
Figure 2 Light microscope images of core-shell microspheres (S/O/Oh/W). (A) Oil phase (12.5% w/w HPLA/PLgA3A); (B) oil phase (12.50% w/w LPLA/PLgA3A); (C) oil 
phase (20% w/w HPLA/PLgA2A); (D) oil phase (20% w/w LPLA/PLgA2A); (E) oil phase (25% w/w HPLA/PLgA1A); (F) oil phase (25% w/w LPLA/PLgA1A). 
Notes: HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-co-glycolide) 
(PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); PLgA2A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 2A [50:50], MW 20,000 units); PLgA1A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 1A [50:50], MW 6500 units); solid phase: 10 mg protein-loaded dextran nanoparticles (BSA/dextran = 1); hydrophilic 
oil: Eg/g = 4(5.5 mL containing 0.5 mL 5% w/w PVA and NaCl); oil phase (PLA/PLgA = 60/40, 800 mg DCM solution). 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene glycol; g, glycerol; PEg, polyethylene glycol; PLA, poly(D,L-lactide); PVA, polyvinyl 
alcohols.
Volume density graph (full scale)
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Figure 3 Size distributions of microspheres. 
Note: The sample is the same as in Figure 2A. 
Abbreviations: SD, standard deviation; vm, volume.
B
D C
A 100 µm 100 µm
100 µm 100 µm
Figure  4  Light  microscope  images  of  core-shell  microspheres.  (A)  (Dextran/
BSA = 1),  HPLA/PLgA3A;  (C)  (dextran/MgB = 1)  LPLA/PLgA3A;  solid phase: 
10 mg protein-loaded dextran nanoparticles (protein/dextran = 1); oil phase: PLA/
PLgA3A = 60/40 (800 mg, 12.5% w/w DCM solution); hydrophilic oil: Eg/g = 4 
(5.7  mL  containing  0.7  mL  5%  PEg,  DCM  solvent);  ethanol  phase:  200  mL. 
(B) (Dextran/BSA = 1); HPLA/PLgA3A; (D) dextran MgB/ = 1); LPLA/PLgA3A.
Notes:  HPLA:  poly(D,L-lactide)  (High  IV)  (MW  40,000–75,000  units);  LPLA: 
poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide- 
co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid 
phase: 10 mg protein-loaded dextran nanoparticles (protein/dextran = 1); oil phase: 
PLA/PLgA3A = 60/40 (800 mg, 12.5% w/w DCM solution); hydrophilic oil: Pg/g = 4 
(5.7 mL containing 0.7 mL, 5% w/w PVP, DCM solution); ethanol phase: 200 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PLA, poly(D,L-lactide); PVA, polyvinyl 
alcohols.
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Table 1 Effect of surfactant on encapsulation efficiency (n = 5)
Formulation Encapsulation efficiency
A 89.96% ± 8.64%
B 52.55% ± 0.61%
C 50.34% ± 5.06%
D 46.50% ± 3.40%
Notes: Surfactant: A, PVP; B, PVA; C, Pluronic F68; and D, PEg. HPLA: poly(D,L-
lactide)  (High  IV)  (MW  40,000–75,000  units);  LPLA:  poly(D,L-lactide)  (Low  IV) 
(MW  40,000–75,000  units);  PLgA3A:  poly(D,L-lactide-co-glycolide)  (PLgA) 
(lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid phase: 15 mg protein-
loaded  dextran  nanoparticles  (dextran/BSA  =  1);  oil  phase:  PLgA  (50/50  3A)/
LPLA = 40/60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: Eg/g = 4 (5.5 mL 
containing 0.8 mL 5% w/w surfactant DCM solution); ethanol phase: 200 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 2A Effect of PLA viscosity on encapsulation efficiency (n = 5)
Formulation Encapsulation efficiency
A 70.84% ± 3.32%
B 69.52% ± 3.74%
Notes: A, high viscosity; B, low viscosity. HPLA: poly(D,L-lactide) (High IV) (MW 
40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); 
PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 
40,000–75,000  units);  solid  phase:  10  mg  protein-loaded  dextran  nanoparticles 
(dextran/BSA = 1); oil phase: PLgA (50/50 3A)/PLA = 40/60 (1000 mg 12.5% w/w, 
DCM); hydrophilic oil: Eg/g = 4 (5.5 mL containing 0.5 mL 4% w/w PVA and NaCl); 
water phase: 5% w/w NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 2B Effect of PLA viscosity on encapsulation efficiency (n = 5)
Formulation Encapsulation efficiency
C 52.55% ± 0.61%
D 45.91% ± 1.11%
Notes: C, MW of PLgA (50/50 3A, MW: 47,000 Da); D, mol wt of PLgA (50/50 
2A, MW: 25,000 Da). HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); 
LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L- 
lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); 
solid phase: 10 mg protein-loaded dextran nanoparticles (dextran/BSA = 1); oil phase: 
PLgA/PLA = 40/60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: Eg/g = 4 (5.5 mL 
containing 0.5 mL 4% w/w PVA and NaCl); ethanol phase: 200 mL.
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 3 Effect of the ratio of PLgA to PLA on encapsulation 
efficiency (n = 5)
Formulation Encapsulation efficiency
C 47.52% ± 1.32%
D 69.52% ± 3.74%
E 45.76% ± 1.54%
Notes: C, PLgA (50/50 3A)/LPLA = 20/80; D, PLgA (50/50 3A)/LPLA = 40/60; 
E,  PLgA  (50/50  3A)/LPLA  =  40/80.  HPLA:  poly(D,L-lactide)  (High  IV)  (MW 
40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); 
PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 
40,000–75,000  units);  solid  phase:  10  mg  protein-loaded  dextran  nanoparticles 
(dextran/BSA = 1); oil phase: PLgA (50/50 3A)/PLA (1000 mg 12.5% w/w, DCM); 
hydrophilic oil: Pg/g = 4 (5.5 mL containing 0.50 mL 4% w/w PVA and NaCl); water 
phase: 5% w/w NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Effect of surfactant
Table 1 shows that the encapsulation efficiency of core-shell 
microspheres decreased with surfactant choice, in the fol-
lowing order: PVP . PVA . Pluronic® F68 . PEG, from 
89.96% ± 8.64% to 46.50% ± 3.40%.
Effect of PLA and PLgA
Table 2A shows that the encapsulation efficiency of core-shell 
microspheres increased with increasing viscosity of PLA solu-
tions in DCM, from 69.52% ± 3.74% to 70.84% ± 3.32%.
Table 2B shows that the encapsulation efficiency of 
core-shell microspheres increased with the increasing PLGA 
  molecular weight, from 45.91% ± 1.11% to 52.55% ± 0.61%.
Effect of the ratio of PLgA to PLA
Table 3 shows that the encapsulation efficiency of core-
shell microspheres changed with increasing ratios of PLGA 
to PLA.
Effect of hydrophilic oil
Table 4A and B shows that the encapsulation efficiency was 
lower for core-shell microspheres prepared in hydrophilic 
oil (EG/G = 4, 5.50 mL containing 0.50 mL 4% w/w PVA 
and NaCl) and hardened in a water phase compared to those 
prepared in hydrophilic oil (PG/G = 4, 5.50 mL containing 
0.50 mL 4% w/w PVA and NaCl), from 74.88% ± 3.48% to 
86.04% ± 0.72%; or from 56.32% ± 7.70% to 86.04% ± 0.72% 
microspheres hardening in the ethanol phase.
Effect of protein loading
Table 5A shows that the encapsulation efficiency of high-
loading core-shell microspheres prepared in hydrophilic oil 
(EG/G = 4, 5.50 mL containing 0.50 mL 4% w/w PVA and 
NaCl) and hardening in water phase is more than low-loading 
microspheres, from 69.94% ± 3.52% to 86.04% ± 0.72%. 
The result was also fit for encapsulation efficiency of core-
shell microspheres prepared in hydrophilic oil (PG/G = 4.00) 
(5.50 mL containing 0.80 mL 5% w/w PVP DCM solution) 
and hardening in water phase (Table 5B).
Protein-loaded dextran nanoparticles 
from core-shell microspheres
To examine the changes of the protein-loaded dextran 
nanoparticles following encapsulation within the core-
shell microspheres, the core-shell microspheres were 
re-dissolved in DCM to remove the PLGA and PLA, 
and solid particles were collected and viewed by SEM. 
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Table 4A Effect of the hydrophilic oil on encapsulation efficiency 
(n = 5)
Formulation Encapsulation efficiency
A 56.32% ± 7.70%
B 91.96% ± 8.64%
Notes: A, hydrophilic oil (Pg/g = 4); B, hydrophilic oil (Eg/g = 4). HPLA: poly 
(D,L-lactide)  (High  IV)  (MW  40,000–75,000  units);  LPLA:  poly(D,L-lactide) 
(Low IV) (MW 40,000–75,000units); PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) 
(lactide:glycolide 3A, (50:50), MW 40,000–75,000units); solid phase: 20 mg protein-
loaded  dextran  nanoparticles  (dextran/BSA  =  1);  oil  phase:  PLgA  (50/50  3A)/ 
LPLA = 40:60 (1000 mg 12.5% W/W, DCM); hydrophilic oil: 5.5 mL containing   
0.8 mL 5% w/w PVP DCM solution; ethanol phase: 200 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 4B Effect of the hydrophilic oil on encapsulation efficiency 
(n = 5)
Formulation Encapsulation efficiency
C 74.88% ± 3.48%
D 86.04% ± 0.72%
Notes:  C,  hydrophilic  oil  (Pg/g  =  4);  D,  hydrophilic  oil  (Eg/g  =  4).  HPLA: 
poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); LPLA: poly(D,L-lactide) (Low 
IV)  (MW  40,000–75,000  units);  PLgA3A:  poly(D,L-lactide-co-glycolide)  (PLgA) 
(lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid phase: 20 mg protein-
loaded  dextran  nanoparticles  (dextran/BSA  =  1);  oil  phase:  PLgA  (50/50  3A)/ 
LPLA = 40:60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: 5.5 mL containing 0.5 mL 
4% w/w PVA and NaCl; water phase: 5% w/w NaCl solution1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 5A Effect of protein loading on encapsulation efficiency 
(n = 5)
Formulation Loading Encapsulation efficiency
A 3.49% ± 0.18% 69.94% ± 3.52%
B 8.60% ± 0.72% 86.04% ± 0.72%
Notes:  A,  solid  phase:  10  mg  protein-loaded  dextran  nanoparticles;  B,  20  mg 
protein-loaded  dextran  nanoparticlesHPLA:  poly(D,L-lactide)  (High  IV)  (MW 
40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); 
PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 
40,000–75,000 units); solid phase: protein-loaded dextran nanoparticles (dextran/
BSA = 1); oil phase: PLgA (50/50 3A)/HPLA = 40:60 (1000 mg 12.5% w/w, DCM); 
hydrophilic oil: Eg/g = 4 (5.5 mL containing 0.5 mL 4% PVA and NaCl); water phase: 
5% NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Table 5B Effect of protein loading on encapsulation efficiency 
(n = 5)
Formulation Loading Encapsulation efficiency
C 3.28% ± 0.19% 65.52% ± 3.74%
D 7.59% ± 0.34% 75.88% ± 3.48%
Notes: C, solid phase:10 mg protein-loaded dextran nanoparticles; D, 20 mg protein-
loaded dextran nanoparticles. HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 
units);  LPLA:  poly(D,L-lactide)  (Low  IV)  (MW  40,000–75,000  units);  PLgA3A: 
poly(D,L-lactide-co-glycolide)  (PLgA)  (lactide:glycolide  3A,  [50:50],  MW  40,000–
75,000 units); solid phase: protein-loaded dextran nanoparticles (dextran/BSA = 1); 
oil phase: PLgA (50/50 3A)/LPLA = 40:60 (1000 mg 12.5% w/w, DCM); hydrophilic 
oil: Pg/g = 4 (5.5 mL containing 0.8 mL 5% w/w PVP DCM solution); water phase:   
5% NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
Figure 5 shows that the morphology of the nanoparticles 
was unchanged.
Aggregations of protein  
from core-shell microspheres
To evaluate protein aggregation, the protein from core-shell 
microspheres and the original protein solution were assessed 
using SEC-HPLC. Protein aggregation was unchanged 
from 82.13% ± 5.23% monomer BSA to 82.08% ± 4.96% 
monomer BSA; 96.52% ± 4.21% monomer myoglobin to 
96.08% ± 5.32% monomer myoglobin (Figure 6).
β-galactosidase activity from core-shell 
microspheres
The activity of β-galactosidase was assessed immedi-
ately from β-galactosidase-loaded dextran nanoparticles 
and again following encapsulation within the core-shell 
  microspheres. The enzyme activity was not significantly 
different from that measured using freshly dissolved 
β-galactosidase (Table 6, P = 0.75).
In vitro protein release
The release efficacy from core-shell microspheres was exam-
ined by investigating the effects of surfactant, hydrophilic oil, 
and protein-loaded dextran nanoparticle loading on in vitro 
protein release.
Effect of hydrophilic oil
Figure 7A and B show the long-term release kinetics for BSA 
from core-shell microspheres made using different hydrophilic 
oils (PG/G and EG/G, respectively) and hardening in an etha-
nol phase of 200 mL. Core-shell microspheres prepared with 
PG/G and EG/G oils showed a burst release near 22% w/w and 
15% w/w, respectively; followed by a gradual release, reaching 
86% w/w and 85% w/w of the loaded amount, respectively, 
over the next 60 days. This is possibly because the hydrophilic 
property of hydrophilic oil from EG/G is better than the 
hydrophilic oil from PG/G. It is easier for the hydrophilic oil 
(EG/G) phase to form interfaces with PLGA/PLA DCM oil 
phase than hydrophilic oil phase from PG/G.
Effect of protein-loaded dextran 
nanoparticles loading
Core-shell microspheres prepared with low and high 
loading of protein-loaded dextran nanoparticles showed a 
burst release of about 9% w/w and 20% w/w, followed by 
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a controlled or sustained release of BSA up to 95% of the 
loaded dose for 60 days, respectively (Figure 8A and B). 
Core-shell microspheres with low- and high-loading pro-
tein-loaded dextran nanoparticles using PG/G and EG/G 
hydrophilic oil showed a burst release of 18% w/w and 43% 
w/w, followed by a sustained release of BSA up to 95% of 
the loaded dose in the next 60 days (Figure 8C and D). How-
ever, the burst release was greater for microspheres made 
from PG/G than from EG/G hydrophilic oil (Figure 8).
Core-shell microsphere effect on the 
ratio and concentration of PLA and PLgA
Figure 9 shows the effect of the ratio of PLA to PLGA on 
distribution for protein-loaded dextran nanoparticles and 
formation of core-shell microspheres. The distribution of 
nanoparticles ranged from whole microsphere, core, to edge, 
and from core, edge, to whole microsphere, with decreases 
in the ratio of PLA to PLGA. Figure 9E shows core and shell 
walls of the microsphere.
Discussion
In 1989, Mathiowitz and Langer developed a novel method 
for the preparation of core-shell microspheres for use as a 
controlled drug delivery system. Their protocol used two 
polymers to form a core and shell morphology through phase 
separation.29 Since then, core-shell microspheres have been 
developed for controlled size distribution,30 improved release 
kinetics, and enhanced biocompatibility and toxicological 
safety, etc.31 However, the above researchers investigated 
the core-shell microsphere system for protein delivery using 
the water-in-oil-in-water (W/O/W) and water-in-oil-in-oil 
A
×
B
3,000 15 kV 500 nm × 3,000 15 kV 500 nm
Figure 5 Scanning electron microscopy of protein-loaded dextran nanoparticles. 
(A) Original nanoparticles and (B) core-shell microspheres.
Notes: (A) Protein-loaded dextran nanoparticles; (B) protein-loaded dextran nano-
particles from core-shell microspheres (sample: Figure 2A).
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Figure 6 Spectra of recovery proteins from PLgA microspheres by SEC-HPLC. (A) Original myoglobin; (B) myoglobin from core-shell double-walled microspheres. [LPLA: 
poly(D,L-lactide) (Low IV)( MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid phase: 
10 mg protein-loaded dextran nanoparticles (protein/dextran = 1); oil phase: PLA/PLgA3A = 60/40 (800 mg, 12.5% w/w DCM solution); hydrophilic oil: Pg/g = 4 (5.7 mL 
containing 0.7 mL, 5% w/w PVP, DCM solution); ethanol phase: 200 mL; (dextran/MgB = 1) LPLA/PLgA3A]; (C) Original BSA; and (D) BSA from core-shell double-walled 
microspheres [LPLA: Poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–
75,000 units); solid phase: 10 mg protein-loaded dextran nanoparticles (BSA/dextran = 1); hydrophilic oil:Eg/g = 4 (5.5 mL containing 0.5 mL 5% w/w PVA and NaCl); oil 
phase (12.50% w/w LPLA/PLgA3A)]. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
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Table 6 β-galactosidase activity from core-shell microspheres 
(n = 5, P = 0.75)
β-galactosidase Activity
Original β-galactosidase solution 98% ± 5.19%
Core-shell microspheres 97% ± 7.34%
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Figure 7 Effect of hydrophilic oil on in vitro release (n = 5). A, hydrophilic oil 
(Pg/g = 4); B, hydrophilic oil (Eg/g = 4). 
Notes:  HPLA:  poly(D,L-lactide)  (High  IV)  (MW  40,000–75,000  units);  LPLA: 
poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-
co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid 
phase: 20 mg protein-loaded dextran nanoparticles (dextran/BSA = 1); oil phase: 
PLgA (50/50 3A)/LPLA = 40:60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: 5.5 mL 
containing 0.8 mL 5% w/w PVP DCM solution; ethanol phase: 200 mL. 
Abbreviations:  BSA,  bovine  serum  albumin;  DCM,  dichloromethane;  PVP, 
polyvinyl-pyrrolidone.
(W/O/O) double emulsion method, which required the protein 
solution to be added directly to a PLGA organic solvent and 
resulted in loss of bioactivity. To overcome the problems,  we 
developed a novel S/O/O/W multi-emulsion method for protein 
delivery systems, but the method is still flawed in terms of 
initial burst release.25 So, we tried to develop a novel core-shell 
microsphere preparation method where the protein was first 
loaded into dextran nanoparticles and then encapsulated within 
core-shell microspheres using a solid-in-oil-in-hydrophilic 
oil-in-water (ethanol) (S/O/Oh/W [E]) process.
The formation of protein-loaded dextran nanoparticles 
or microparticles using aqueous phase–aqueous phase 
emulsions or low freezing phase separation methods has 
been investigated as a way to protect proteins during the 
encapsulation procedure.21–24 The protein-loaded dextran 
nanoparticles formed through a low freezing phase separa-
tion method were chosen for use in this study because these 
are small size particles. The small size of the protein-loaded 
dextran nanoparticles was hypothesized to help in distribu-
tion within the initial PLGA solution, which would lead to a 
decrease in protein aggregation and therefore an improvement 
in retention of protein bioactivity.
An aqueous protein solution will readily self-assemble into a 
PLGA core using the oil-in-oil-in-water (O/O/W) or water-in-oil-
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Figure 8 The effect of protein-loaded dextran nanoparticles loading on in vitro 
protein release (n = 5). (A) Solid phase: 10 mg protein-loaded dextran nanoparticles; 
(B)  20  mg  protein-loaded  dextran  nanoparticles.  Solid  phase:  protein-loaded 
dextran  nanoparticles  (dextran/BSA  =  1);  oil  phase:  PLgA  (50/50  3A)/LPLA  = 
40:60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: Pg/g = 4 (5.5 mL containing 
0.8  mL  5%  w/w  PVP  DCM  solution);  water  phase:  5%  NaCl  solution1000  mL;   
(C) solid phase: 10 mg protein-loaded dextran nanoparticles; (D) 20 mg protein-
loaded dextran nanoparticles.
Notes:  HPLA:  poly(D,L-lactide)  (High  IV)  (MW  40,000–75,000  units);  LPLA: 
poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide -co-
glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); solid 
phase:  protein-loaded  dextran  nanoparticles  (dextran/BSA  =  1);  oil  phase: 
PLgA  (50/50  3A)/HPLA  =  40:60  (1000  mg  12.5%  w/w,  DCM);  hydrophilic  oil:   
Eg/g = 4 (5.5 mL containing 0.5 mL 4% PVA and NaCl); water phase: 5% NaCl 
solution 1000 mL.
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols; PVP, polyvinyl-
pyrrolidone.
in-oil (W/O/O) double emulsion process.9 However, the question 
of whether protein-loaded dextran nanoparticles will distribute 
into a PLGA core using solid-in-oil-in-water (S/O/W) or solid-
in-oil-in-oil (S/O/O) double emulsion remained unanswered. 
We addressed this question by two methods and confirmed that 
nanoparticles could be distributed into a PLGA core.
The ratio of PLA to PLGA affected the distribution of the 
protein-loaded dextran nanoparticles within the   microsphere 
(Figures 9 and Figure S3). When the amount of PLGA 
was low, no phase separation occurred between PLA and 
PLGA. When matched amounts of PLGA were supplied, 
both polymer phases separated. Because the nanoparticles 
were hydrophilic and readily interacted with hydrophilic 
PLGA, this resulted in the nanoparticles localizing within 
the core of the microspheres. When the amount of PLGA 
was equivalent, the PLGA microspheres could not engulf 
the PLA microspheres, which resulted in localization of the 
nanoparticles on the edges of the core-shell microspheres.
When the amount of PLGA was high, the PLA and PLGA 
again could not undergo phase separation, but the nanopar-
ticles appeared within whole microspheres. These effects 
were probably due to the similar hydrophilicities of dextran 
nanoparticles and the PLGA solution, which resulted in more 
dextran nanoparticle distribution within the PLGA core of 
microspheres and fewer nanoparticles on the surface and 
shell of the microspheres. The nanoparticles on the surface 
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Figure 9 Scanning electron microscopy of microspheres formed using different 
ratios of PLgA and PLA (S/O/Oh/W). (A) PLA/PLgA = 80/20; (B and C) PLA/ 
PLgA = 50/50; (D) PLA/PLgA = 80/40; (E) cross-sectional images of core-shell 
double-walled polymer microspheres (PLA/PLgA = 60/40).
Notes:  LPLA:  Poly(D,L-lactide)  (Low  IV)  (MW  40,000–75,000  units);  PLgA3A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–
75,000 units); solid phase: 10 mg protein-loaded dextran nanoparticles (dextran/
BSA = 1.00); oil phase: PLgA (50/50 3A)/LPLA (1000 mg 12.50% w/w, DCM); 
hydrophilic oil: Eg/g = 4.00 (5.50 mL containing 0.50 mL 4% PVA and NaCl); water 
phase: 5% NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PVA, polyvinyl alcohols.
and shell would directly encounter the oil–water interfaces, 
which would lead to loss of protein bioactivities.
Encapsulation efficiency was also greatly affected by dif-
ferent surfactants, the molecular weight of PLGA and PLA, 
the ratio of PLGA to PLA, loading, and the formulation of the 
hydrophilic oil used during the process of fabrication. The best 
results occurred when the following conditions were met: (1) 
the activities and film-forming properties of the surfactants 
were optimal; (2) the viscosities and the ratios of PLGA and 
PLA were matched; (3) the protein loading was matched; (4) 
the hydrophilicity of the hydrophilic oil phase was optimal.
The protein-release kinetics in vitro from core-shell 
microspheres was also affected by many factors such as 
surfactant, hydrophilic oil choice, and protein-loaded dextran 
nanoparticle loading. When the activities and film-forming 
properties of surfactants were excellent, the release kinetics 
in vitro were also excellent and showed low burst release   
(eg, PVP in Figure S2). It is possible that protein release from 
protein-loaded dextran nanoparticles adsorbed to the PLA 
surface differed from that released from within the PLA 
shell. In addition, PEG could enhance the porosity of the 
microspheres, resulting in a burst release pattern in the order 
of PVP , Pluronic F68 , PEG (Figure S2).
When the hydrophilicities of the hydrophilic oil phase and 
the polymer organic solution phases were different, the release 
kinetics were also different (Figures 7 and 8). The in vitro 
release kinetics were close to zero order,   possibly because: (1) 
a better choice of hydrophilic oil phase,   surfactant, and loading 
resulted in more nanoparticles encapsulated within the PLGA 
core and fewer on the shell and surface; (2) the release kinetics 
profile for BSA reveals that protein was delivered first from the 
surface of the microsphere and then from within the PLA shell, 
followed by formation of macropores in the PLA microsphere 
shells and slow rupture. The slow, zero-order release of BSA 
between day 1 and day 40 reflects the high water uptake of the 
inner PLGA core and dextran and the beginning of swelling and 
dissolution, resulting in short-term changes in the amount of 
BSA diffused into the external water phase. Increasing osmotic 
pressure, in addition to the molecular weight of dextran being 
greater than that of BSA, and bulk degradation of the PLGA 
core bulk degradation eventually resulted in an increased rate 
of BSA diffusion into the external water phase from the core; 
these factors led to the release-kinetics profile observed.
Figure 8 shows the in vitro release profiles of low- and high-
loading protein-loaded dextran nanoparticles. Burst release 
was lower with low loading than with high loading. This was 
probably because more high-loading particles distributed near 
the surfaces and shells of the microspheres. We observed that 
the nanoparticles were distributed near the surfaces and shell 
with the high-loading microspheres (Figure S5A and B).
Conclusion
Core-shell microspheres were prepared using solid-in-oil-in-
hydrophilic oil-in-water or ethanol (S/O/Oh/W or E). Initial 
studies with microspheres encapsulating BSA-loaded dextran 
nanoparticles and horse myoglobin-loaded dextran nano-
particles indicated that protein-loaded dextran nanoparticle 
localization was restricted to the PLGA core. The recovered 
nanoparticles from the microspheres indicated that the encap-
sulated dextran nanoparticles almost changed. In addition, 
protein release studies were performed using core-shell micro-
spheres with the model protein BSA-loaded dextran nanopar-
ticles encapsulated using different surfactants and loadings, 
etc. The results confirmed that protein could achieve zero-order 
release for at least 40 days by adjusting different surfactants, 
loadings et al. Based on these results, it is suggested that the 
method could be used to create potential vehicles for long-
efficacy delivery of protein drugs and cell factors.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
266
Yuan and LiuInternational Journal of Nanomedicine 2012:7
Acknowledgments
Weien Yuan performed all tests and experiments; data analysis 
and interpretation were performed by Zhenguo Liu.
The study was supported by the Project of National 
Science Foundation of China Committee (81071025 and 
81171203), Shanghai Science and Technology Committee of 
Science and Technology Special Nanotechnology Grant (No. 
1052nm03900 and No. 11nm0503300), the Key Foundational 
Program of the Shanghai Committee of Science and Technol-
ogy, China (No. 09JC14 11000), PhD Programs Foundation of 
Ministry of Education of China (No. 20090073120085), and 
University Student Renovation Project of Shanghai Jiao Tong 
University (IPP2090). And we also appreciate the generous 
help from faculty members of the Institute of Instrumental 
Analysis Centre (IAC) of Shanghai Jiao Tong University.
Disclosure
The authors report no competing financial interests in this 
work.
References
  1.  Wise DL, Trantolo DJ, Marino RT, Kitchell JP. Opportunities and 
  challenges in the design of implantable biodegradable polymeric 
  systems for the delivery of anti-microbial agents and vaccines. Adv 
Drug Deliv Rev. 1987;1:19–39.
  2.  Patel ZS, Yamamoto M, Ueda H, Tabata Y, Mikos AG. Biodegradable 
gelatin microparticles as delivery systems for the controlled release of 
bone morphogenetic protein-2. Acta Biomater. 2008;4:1126–1138.
  3.  Lee GS, Park JH, Shin US, Kim HW. Direct deposited porous scaffolds 
of calcium phosphate cement with alginate for drug delivery and bone 
tissue engineering. Acta Biomater. 2011;7:3178–3186.
  4.  King WJ, Toepke MW, Murphy WL. Facile formation of dynamic 
hydrogel microspheres for triggered growth factor delivery. Acta 
Biomater. 2011;7:975–985.
  5.  Cleland JL, Lim A, Barron L, Duenas ET, Powell MF. Development 
of a single-shot subunit vaccine for HIV-1: Par 4. Optimizing micro-
encapsulation and pulsatile release of MNrgp120 from biodegradable 
microspheres. J Control Release. 1997;47:135–150.
  6.  Cleland JL. Single-administration vaccines: controlled-release technol-
ogy to mimic repeated immunizations. Trends Biotechnol. 1999;17: 
25–29.
  7.  Jain R, Shah N, Malick A, Rhodes C. Controlled drug delivery by 
biodegradable poly(ester) devices: different preparative approaches. 
Drug Dev Ind Pharm. 1998;24(8):703–727.
  8.  Fu K, Harrell R, Zinski K, et al. A potential approach for decreasing the 
burst effect of protein from PLGA microspheres. J Pharm Sci. 2003; 
92(8):1582–1591.
  9.  Rothstein SN, Federspiel WJ, Little SR. A simple model framework 
for the prediction of controlled release from hydrated biodegradable 
polymer matrices. J Mat Chem. 2008;18:1873–1880.
  10.  Rothstein SN, Federspiel WJ, Little SR. A unified mathematical model 
for the prediction of controlled release from surface and bulk eroding 
polymer matrices. Biomaterials. 2009;30(8):1657–1664.
  11.  van de Weert M, Hennink WE, Jiskoot W. Protein instability in 
poly(lactic-coglycolic acid) microparticles. Pharm Res. 2000;17(10): 
1159–1167.
  12.  Ciombor DM, Jaklenec A, Liu AZ, et al. Encapsulation of BSA using a 
modified W/O/O emulsion solvent removal method. J Microencapsul. 
2006;23(2):183–194.
  13.  Lee WL, Loei C, Widjaja E, Loo SCJ. Altering the drug release profiles 
of double-layered ternary-phase microparticles. J Control Release. 
2011;151:229–238.
  14.  Srinivasan C, Katare YK, Muthukumaran T, Panda AK. Effect 
of   additives on encapsulation efficiency, stability and bioactiv-
ity of entrapped lysozyme from biodegradable polymer particles.   
J   Microencapsul. 2005;22(2):127–138.
  15.  Choi DH, Park CH, Kim IH, Chun HJ, Park K, Han DK. Fabrication 
of core–shell microcapsules using PLGA and alginate for dual growth 
factor delivery system. J Control Release. 2010;147:193–201.
  16.  Lee TH, Wang J, Wang C-H. Double-walled microspheres for the 
sustained release of a highly water soluble drug: characterization and 
irradiation studies. J Control Release. 2002;83(3):437–452.
  17.  Tan EC, Lin R, Wang C-H. Fabrication of double-walled microspheres 
for the sustained release of doxorubicin. J Colloid Interface Sci. 2005; 
291(1):135–143.
  18.  Babu VR, Sairam M, Hosamani KM, Aminabhavi TM. Development 
of 5-fluorouracil loaded poly(acrylamide-co-methylmethacrylate) 
novel core-shell microspheres: In vitro release studies. Int J Pharm. 
2006;325:55–62.
  19.  Berkland C, Cox A, Kim K, Pack DW. Three-month, zero-order piroxi-
cam release from monodispersed double-walled microspheres of con-
trolled shell thickness. J Biomed Mater Res A. 2004;70(4):576–584.
  20.  Matsumoto A, Matsukawa Y, Suzuki T, Yoshino H, Kobayashi M. 
The polymer alloy method as a new preparation method of biode-
gradable microspheres: Principle and application to cisplatin-loaded 
  microspheres. J Control Release. 1997;48:19–27.
  21.  Jin T, Zhu J, Wu F, Yuan W, Zhu H, Geng L. Preparing polymer-based 
sustained-release systems without exposing protein to water–oil or 
water–air interface and cross-linking reagents. J Control Release. 2008; 
128(1):50–59.
  22.  Yuan W, Geng Y, Wu F, et al. Preparation of polysaccharide glassy 
nanoparticles with stabilization of proteins. Int J Pharm. 2009; 
366:154–159.
  23.  Yuan W, Wu F, Geng Y, Xu S, Jin T. Preparation of dextran glassy 
particles through freezing-induced phase separation. Int J Pharm. 
2007;339:76–83.
  24.  Ren T, Yuan W, Zhao H, Jin T. Sustained-release polylactide-co- 
glycolide microspheres loaded with pre-formulated protein polysac-
charide nanoparticles. Micro Nano Lett. 2011;6(2):70–74.
  25.  Yuan W, Wu F, Guo M, Jin T. Development of protein delivery micro-
sphere system by a novel S/O/O/W multi-emulsion. Eur J Pharm Sci. 
2009;36:212–218.
  26.  Yuan W, Zhang Y, Wu F, et al. Preparation of protein-loaded sustained-
release microspheres via “solid-in-oil-in-hydrophilic oil-in-ethanol 
(S/O/hO/E)” emulsification. Colloids Surf B Biointerfaces. 2010; 
79(2):326–333.
  27.  Volkin DB, Klibanov AM. Minimizing protein inactivation.   
In:   Creighton TE, editor. Protein Function: A Practical Approach. 
Oxford: Information Press, 1989:1–24.
  28.  Kokai LE, Huaping T, Jhunjhunwala S, Little SR, Frank JW, Marra KG. 
Protein bioactivity and polymer orientation is affected by stabilizer 
incorporation for double-walled microspheres. J Control Release. 2010; 
141:168–176.
  29.  Mathiowitz E, Langer R. Preparation of multiwall polymeric micro-
capsules from hydrophilic polymers, United States Patent (5985354), 
August 29, 1989.
  30.  Berkland C, Pollauf E, Pack DW, Kim K. Uniform double-walled poly-
mer microspheres of controllable shell thickness. J Control Release. 
2004;96:101–111.
  31.  Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA 
and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5–24.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
267
Proteins from core-shell double-walled microspheresInternational Journal of Nanomedicine 2012:7
Supplementary data
Effect of surfactant
Figure S2 shows the long-term release kinetics for BSA 
from core-shell microspheres made using different sur-
factants (PVP, Pluronic F68, and PEG) in PBS (pH 7.4). 
Core-shell microspheres prepared with PEG showed a 
high burst release (near 60% w/w) followed by a gradual 
release, reaching 98% w/w of the loaded amount over the 
next 60 days.   Microspheres made with Pluronic F68 and 
PVP showed high burst release near 40% w/w and near 
20% w/w, respectively; followed by a gradual release, 
reaching 80% w/w and 82% w/w of the loaded amount, 
respectively, over the next 60 days.
Effect of hydrophilic oil
Core-shell microsphere effect on the ratio  
and concentration of PLA and PLgA
Figure S3 shows the effect of the ratio of PLA to PLGA on 
distribution for protein-loaded dextran nanoparticles and 
AB B 100 µm
D DC C
A
EFEF
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm 100 µm
100 µm 100 µm 100 µm 100 µm
I: Microspheres in the hydrophilic oil II: Hardening microspheres in the water phase
Figure S1 Light microscope images of core-shell microspheres. (A) oil phase (12.5% w/w HPLA/PLgA3A); (B) oil phase (12.5% w/w LPLA/PLgA3A); (C) oil phase (20% w/w 
HPLA/PLgA2A); (D) oil phase (20% w/w LPLA/PLgA2A); (E) oil phase (25% w/w HPLA/PLgA1A); (F) oil phase (25% w/w LPLA/PLgA1A = 60/40). 
Notes: HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-co-glycolide) 
(PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–75,000 units); PLgA2A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 2A (50:50), MW 20000 units); PLgA1A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 1A (50:50), MW 6500 units); solid phase: 10 mg protein-loaded dextran nanoparticles (BSA/dextran = 1); hydrophilic 
oil: Pg/g = 4 (5.5 mL containing 0.5 mL 5% w/w PVA and NaCl); oil phase: (PLA/PLgA = 60/40, 800 mg, DCM solution). 
Abbreviations: BSA, bovine serum albumin; DCM,dichloromethane; Pg,1,2-propylene glycol; g,glycerol; PLA, poly(D,L-lactide); PVA, polyvinyl alcohols.
formation of core-shell microspheres. The distribution of 
nanoparticles ranged from whole microsphere, core, to edge, 
and from core, edge, to whole microsphere, with decreases 
in the ratio of PLA to PLGA.
Figure S4 shows that when the concentration of PLGA 
and PLA was more than 12.5% w/w, the protein-loaded 
dextran nanoparticles were distributed in the PLGA core of 
the microspheres and formed core-shell microspheres. The 
result was the same as the formation of core-shell micro-
spheres using the phase separation method according to the 
phase separation of PLGA and PLA at certain concentrations. 
However, the nanoparticles were distributed near the surfaces 
and shell with the high-loading microspheres.
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Figure S2 Effect of surfactant on in vitro protein release (n = 5). 
Notes: HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000units); PLgA3A: poly(D,L-lactide-co-glycolide) 
(PLgA) (lactide:glycolide 3A, (50:50), MW 40,000–75,000 units); solid phase: 15 mg protein-loaded dextran nanoparticles (dextran/BSA = 1); oil phase: PLgA (50/50 3A)/
LPLA = 40/60 (1000 mg 12.5% w/w, DCM); hydrophilic oil: Eg/g = 4 (5.5 mL containing 0.8 mL 5% w/w surfactant DCM solution); ethanol phase: 200 mL; surfactant: PVP, 
Pluronic F68 and PEg. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg,ethylene glycol; g, glycerol; PEg, polyethylene glycol; PLA, poly(D,L-lactide); PVA, polyvinyl 
alcohols.
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Figure S3 Light microscope images of microspheres formed using different ratios of PLgA and PLA. (A) PLgA/PLA = 80/20; (B) PLgA/PLA = 80/40; (C) PLgA/PLA = 60/40;   
(D) PLgA/PLA = 50/50; (E) PLgA/PLA = 40/60; (F) PLgA/PLA = 40/80; and (G) PLgA/PLA = 20/80; (G) solid phase: 10 mg protein-loaded dextran nanoparticles (dextran/
BSA = 1.00); oil phase: LPLA/PLgA (50/50 3A) = 60/40 (1000 mg 12.50% w/w, DCM); water phase: 5% NaCl and 4% PVA solution 1000 mL. 
Notes: HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); LPLA: poly(D,L-lactide) (Low IV) (MW 40,000–75,000 units); PLgA3A: poly(D,L-lactide-co-glycolide) 
(PLgA) (lactide:glycolide 3A [50:50], MW 40,000–75,000 units); PLgA2A: poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 2A [50:50], MW 20,000 units); PLgA1A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 1A (50:50), MW 6500 units); solid phase: 10 mg protein-loaded dextran nanoparticles (dextran/BSA = 1.00); oil phase: 
PLg (50/50 3A)/LPLA (1000 mg 12.50% w/w, DCM); hydrophilic oil: Eg/g = 4.00 (5.50 mL containing 0.50 mL 4% PVA and NaCl); water phase: 5% NaCl solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene glycol; g, glycerol; PEg, polyethylene glycol; PLgA, poly(D,L-lactide-co-glycolide); PVA, 
polyvinyl alcohols.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
269
Proteins from core-shell double-walled microspheresInternational Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7
B
D C
A 100 µm 100 µm
100 µm 100 µm
Figure  S4  Light  microscope  images  of  microspheres  formed  using  different 
concentrations  of  PLgA  and  PLA.  Concentration  of  PLg  (50/50  3A)/LPLA: 
(A) 15% w/w; (B) 12.5% w/w; (C) 10% w/w; (D) 7.5% w/w. 
Notes:  LPLA:  poly(D,L-lactide)  (Low  IV)  (MW  40,000–75,000  units);  PLgA3A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–
75,000 units); solid phase: 10 mg protein-loaded dextran nanoparticles (dextran/ 
BSA = 1.00); oil phase: PLg (50/50 3A)/LPLA = 40/60; hydrophilic oil: Eg/g = 4.00 
(5.50 mL containing 0.50 mL 4% PVA and NaCl); water phase: 5% NaCl solution. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PLgA, poly(D,L-lactide-co-glycolide); 
PVA, polyvinyl alcohols.
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Figure  S5  Light  microscope  images  of  microspheres  with  different  loadings.   
(A) Solid phase: 10 mg protein-loaded dextran nanoparticles; (B) 20 mg protein-
loaded dextran nanoparticles. 
Notes: HPLA: poly(D,L-lactide) (High IV) (MW 40,000–75,000 units); PLgA3A: 
poly(D,L-lactide-co-glycolide) (PLgA) (lactide:glycolide 3A, [50:50], MW 40,000–
75,000 units); solid phase: protein-loaded dextran nanoparticles (dextran/BSA = 1); 
oil phase: PLgA (50/50 3A)/HPLA = 40:60 (1000 mg 12.5% w/w, DCM); hydrophilic 
oil: Eg/g = 4 (5.5 mL containing 0.5 mL 4% PVA and NaCl); water phase: 5% NaCl 
solution 1000 mL. 
Abbreviations: BSA, bovine serum albumin; DCM, dichloromethane; Eg, ethylene 
glycol; g, glycerol; PEg, polyethylene glycol; PVA, polyvinyl alcohols.
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